ConductScience.org, home

Paper37554517

Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex.

Tollenaere MAX and 6 others. JID Innov, 2023. Cited by 18 papers, by iCite.

Cite this record

ConductScience Library. Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex. Papers, record 37554517. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37554517

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex.
PubMed
Journal
JID Innov
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
2.04
iCite
Revised in PubMed
2023-08-10
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tollenaere MAXMaxim A X
2Mølck CChristina
3Henderson IIan
4Pollack SScott
5Addis PPhilip
6Petersen HHHelle Heibroch
7Norsgaard HHanne

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127956146Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2.J Mol Biol2017https://conductscience.org/library/papers/27956146PubMed
212642601Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response.J Exp Med2003https://conductscience.org/library/papers/12642601PubMed
331230370Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis.Allergy2020https://conductscience.org/library/papers/31230370PubMed
429772180Determination of Affinity and Residence Time of Potent Drug-Target Complexes by Label-free Biosensing.J Med Chem2018https://conductscience.org/library/papers/29772180PubMed
59013879Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex.FEBS Lett1997https://conductscience.org/library/papers/9013879PubMed
620223216Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2.Structure2010https://conductscience.org/library/papers/20223216PubMed
78552669Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor.Proc Natl Acad Sci U S A1996https://conductscience.org/library/papers/8552669PubMed
828660216Chitinase-3-Like Protein 1 (YKL-40) Reflects the Severity of Symptoms in Atopic Dermatitis.J Immunol Res2017https://conductscience.org/library/papers/28660216PubMed
912354755Kinetic analysis of the interleukin-13 receptor complex.J Biol Chem2002https://conductscience.org/library/papers/12354755PubMed
1018243101Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system.Cell2008https://conductscience.org/library/papers/18243101PubMed
1111786536A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor alpha -2 and their rapid mobilization by interferon-gamma.J Biol Chem2002https://conductscience.org/library/papers/11786536PubMed
1212642602Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2.J Exp Med2003https://conductscience.org/library/papers/12642602PubMed
1331397016Chitinase 3-like 1 drives allergic skin inflammation via Th2 immunity and M2 macrophage activation.Clin Exp Allergy2019https://conductscience.org/library/papers/31397016PubMed
1417030238IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts.J Allergy Clin Immunol2006https://conductscience.org/library/papers/17030238PubMed
1512642599Decoy receptors in the regulation of T helper cell type 2 responses.J Exp Med2003https://conductscience.org/library/papers/12642599PubMed
1616327802IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis.Nat Med2006https://conductscience.org/library/papers/16327802PubMed
1731838750Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation.Allergy2020https://conductscience.org/library/papers/31838750PubMed
1821622864IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2.J Immunol2011https://conductscience.org/library/papers/21622864PubMed
198910586cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.J Biol Chem1996https://conductscience.org/library/papers/8910586PubMed
2033000465Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).Br J Dermatol2021https://conductscience.org/library/papers/33000465PubMed

See all 37 referencesDownload CSV of references

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
42825999Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison.Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/42825999PubMed
42702765Real-World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis.Clin Transl Allergy2026https://conductscience.org/library/papers/42702765PubMed
42459660Immunomodulatory effects of nematode-microbiota interactions in cancer therapy.Front Immunol2026https://conductscience.org/library/papers/42459660PubMed
42360589
A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'".
Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/42360589PubMed
42033591Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial.Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/42033591PubMed
41642555Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/41642555PubMed
40767793Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action.J Invest Dermatol2025https://conductscience.org/library/papers/40767793PubMed
40721559Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16.Dermatol Ther (Heidelb)2025https://conductscience.org/library/papers/40721559PubMed
40418285Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations.Am J Clin Dermatol2025https://conductscience.org/library/papers/40418285PubMed
40085349Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.Am J Clin Dermatol2025https://conductscience.org/library/papers/40085349PubMed
39820896Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment.Am J Clin Dermatol2025https://conductscience.org/library/papers/39820896PubMed
39673366Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels.Allergy2025https://conductscience.org/library/papers/39673366PubMed
39385749Type 2 Cytokine-Dependent Skin Barrier Regulation in Personalized 2-Dimensional and 3-Dimensional Skin Models of Atopic Dermatitis: A Pilot Study.JID Innov2025https://conductscience.org/library/papers/39385749PubMed
39122503Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab.Dermatol Pract Concept2024https://conductscience.org/library/papers/39122503PubMed
38398754Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma.Life (Basel)2024https://conductscience.org/library/papers/38398754PubMed

Download CSV of cited by

Genes10

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37554517

GET https://conductscience.org/api/papers/v1/37554517/references?page=2